Overview
The purpose of this cohort study is to develop a reliable biomarker in progressive nuclear palsy (PSP).
Description
Progressive supranuclear palsy is a rapidly progressive neurodegenerative disease without a cure. Thus, the development of a biomarker that reflects and monitors disease severity in PSP is critical for early diagnosis and performing a successful clinical trial. Thus, we will prospectively recruit patients with PSP and collect comprehensive clinical, imaging and blood biomarkers at baseline with longitudinal follow-up for 1 year.
Eligibility
Inclusion Criteria for the patient group:
- Age 50 to 80 years, male or female
- Progressive supranuclear palsy (PSP) patients who are diagnosed as Probable, Possible or suggestive PSP with Movement Disorder society diagnostic criteria for PSP (Hoglinger et al., 2017)
Exclusion Criteria for the patient group:
- Subjects with clinically significant psychiatric illness
- Subjects with cancer or severe medical illness
- Lactating, pregnant, or possibly pregnant
- Subjects with small vessel disease (> grade II) in brain MRI or other structural lesions by causes other than PSP
- Subjects with severe dementia patients (MMSE < 19 or MoCA <13 or General deterioration scale >= 5)
Inclusion Criteria for the healthy control group:
- Age 50 to 80 years, male or female
- Those who agreed to participate in this study
Exclusion Criteria for the healthy control group:
- Those with a history of any neurological diseases
- Lactating, pregnant, or possibly pregnant
- Subjects with clinically significant psychiatric illness
- Subjects with cancer or severe medical illness
